Patient case: 54-year-old male with Gastric cancer. Genetic variant: PIK3CA (E545K). Other conditions: Depression.

Clinical trial: Feasibility Study of CDDP + CPT-11 + PSK for Extensive-Stage Disease (ED) Small Cell Lung Cancer

Summary: The purpose of this study is to examine whether setting test groups of cisplatin + irinotecan + Krestin therapy as first-line treatment and chemotherapy (radiotherapy or radiotherapy + chemotherapy also allowed) combined with Krestin as second-line treatment after exacerbation and comparing with historical control or community control is appropriate as the protocol and regimen for the phase III clinical trial on extensive-stage disease (ED) small cell lung cancer.

Detailed description: To examine whether the following protocol and regimen is appropriate for the phase III clinical trial on extensive-stage disease (ED) small cell lung cancer: set test groups of cisplatin + irinotecan + Krestin therapy as first-line treatment and chemotherapy (radiotherapy or radiotherapy + chemotherapy also allowed) combined with Krestin as second-line treatment after exacerbation, evaluate the efficacy and safety of treatment in a small number of cases, and compare with historical control or community control.

Eligibility: Inclusion Criteria:
  -  Patients with histologically or cytologically proven small cell lung cancer
  -  Patients receiving chemotherapy for the first time
  -  Patients with no indication for radical radiotherapy or surgical resection
  -  Patients diagnosed as ED* by full staging [chest X ray, chest C, brain CT or MRI, abdominal CT or abdominal ultrasonography, whole body bone scintigraphy (may be replaced by PET/CT)]
  -  ED: Patient with distant metastasis including contralateral hilar lymph node metastasis, but ipsilateral pleural effusion without distant metastasis is excluded.
  -  Patients with lesions measurable or evaluable by the RECIST criteria
  -  Patients aged from 20 years to below 75 years
  -  Patients with preserved organ functions as indicated by the following test values (data obtained within 14 days prior to registration) Hemoglobin: ≥9.0 g/dL White blood cell count: ≥4,000/mm3, ≤12,000 /mm3 Neutrophil count: ≥ 2,000/mm3 Platelet count: ≥100,000 /mm3 GOT, GPT: below 2.5 times the upper limit of normal range for individual facility Total bilirubin: ≤1.5 mg/dL Serum creatinine: below the lower limit of normal range for individual facility Creatinine clearance: ≥ 60mL/min Arterial oxygen tension （PaO2）: ≥60 torr (resting)
  -  Performance status (PS): 0-1
  -  Absence of serious concurrent cardiac or pulmonary disease
  -  Patients expected to survive for at least 3 months
  -  Patients from whom written informed consent can be obtained
  Exclusion Criteria:
  -  Patients with serious infection and other serious complications (including gastrointestinal bleeding and diarrhea)
  -  Patients with pleural effusion, ascites, or pericardial effusion that requires treatments including puncture drainage and intracavity administration
  -  Patients showing definite interstitial pneumonitis or pulmonary fibrosis on plain chest radiograph
  -  Patients manifesting central nervous system symptoms due to brain metastasis at registration
  -  Patients with active multiple cancers
  -  Patients who had undergone bone marrow transplantation
  -  Patients who had undergone peripheral blood stem cell transplantation
  -  Patients with a history of definite drug allergy
  -  Pregnant and nursing patients, patients who may be pregnant or who intend to become pregnant
  -  Male patients with reproductive capacity who have no intention of contraception during the clinical trial
  -  Patients with poorly controlled diabetes
  -  Patients who had been administered Krestin in the past
  -  Others: patients who are judged by the investigator or subinvestigator to be unsuitable as subject

Relevance to patient case: not relevant